Abstract
The in vitro activity of norfloxacin, a new quinolone derivative, was tested against 469 clinical isolates derived mainly from urinary samples from outpatients. It inhibited all Escherichia coli, Klebsiella oxytoca and Proteus strains at a concentration of 0.25 micrograms/ml, and all Pseudomonas aeruginosa, Enterobacter, Klebsiella pneumoniae, Staphylococcus and Enterococcus strains at a concentration of 8 micrograms/ml or less. Norfloxacin proved to be more effective than nalidixic acid, trimethoprim, mecillinam and nitrofurantoin against all gram-negative rods tested.
MeSH terms
-
Anti-Infective Agents, Urinary / pharmacology*
-
Cefaclor / pharmacology
-
Enterobacteriaceae / drug effects*
-
Enterobacteriaceae Infections / microbiology
-
Humans
-
Microbial Sensitivity Tests
-
Nalidixic Acid / analogs & derivatives*
-
Nalidixic Acid / pharmacology
-
Norfloxacin
-
Penicillins / pharmacology
-
Staphylococcal Infections / microbiology
-
Staphylococcus / drug effects*
-
Streptococcal Infections / microbiology
-
Streptococcus / drug effects*
-
Urinary Tract Infections / microbiology*
Substances
-
Anti-Infective Agents, Urinary
-
Penicillins
-
Nalidixic Acid
-
Cefaclor
-
Norfloxacin